The class of "AA987161 Inhibitors" comprises a diverse range of chemical compounds, each characterized by distinct biochemical properties and specific modes of action. While these compounds are not directly linked to AA987161 due to limited scientific data, they are known to modulate various cellular signaling pathways and processes that could indirectly influence the activity of proteins encoded by this gene or functionally similar proteins.
Zoledronate, as a bisphosphonate, impacts bone metabolism and calcium signaling, pathways that are crucial in various cellular processes including cell differentiation and apoptosis. Canertinib and Neratinib, as tyrosine kinase inhibitors targeting EGFR and Pan-HER respectively, play a significant role in cell growth and survival signaling pathways, which might influence the activity of proteins related to AA987161. Flavopiridol, a CDK inhibitor, affects cell cycle regulation and transcriptional control, highlighting its potential in modulating proteins involved in these critical cellular functions.
Bosutinib and Dasatinib, targeting Src/Abl and multiple tyrosine kinases, respectively, underscore their role in affecting cell survival and proliferation pathways. Temsirolimus, an mTOR inhibitor, and Vorinostat, a histone deacetylase inhibitor, affect key processes like cell growth, proliferation, autophagy, and gene expression, potentially impacting proteins functionally similar to those encoded by AA987161.
Ruxolitinib's inhibition of JAK1/2 affects cytokine signaling and immune response, illustrating the potential to influence proteins involved in these pathways. Ponatinib, a multi-kinase inhibitor, and Palbociclib, a CDK4/6 inhibitor, showcase diverse mechanisms of action, impacting cell signaling related to growth, survival, and
cell cycle regulation. Lenvatinib, another multi-kinase inhibitor, targets pathways crucial for angiogenesis and cell proliferation, demonstrating the breadth of potential indirect effects on proteins similar to those encoded by AA987161.
In summary, the "AA987161 Inhibitors" class, though theoretical, represents a comprehensive approach to understanding and potentially modulating cellular signaling pathways and processes. These compounds serve as valuable tools for research into the functional aspects of proteins and their roles in various cellular processes. While direct inhibitors of AA987161 are not identified due to the lack of detailed information on the protein, this class of inhibitors presents a broad method for exploring the modulation of protein activity within complex cellular networks. Their diverse mechanisms of action, from targeting key signaling molecules like tyrosine kinases and CDKs to affecting gene expression and metabolic pathways, highlight the intricate balance of cellular processes. This diverse range of compounds offers insights into the potential regulation of proteins encoded by genes like AA987161, underscoring the complexity and interconnectedness of cellular signaling pathways. These insights are invaluable for advancing our understanding of cellular biology and the intricate mechanisms that govern cellular function and response in various biological contexts.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Canertinib | 267243-28-7 | sc-207397 | 10 mg | $260.00 | 3 | |
EGFR tyrosine kinase inhibitor, potentially influencing cell growth and survival pathways. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $254.00 | 41 | |
CDK inhibitor, potentially affecting cell cycle regulation and transcriptional control. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Histone deacetylase inhibitor, potentially influencing gene expression and chromatin remodeling. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Broad-spectrum tyrosine kinase inhibitor, potentially affecting multiple cell signaling pathways. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
JAK1/2 inhibitor, potentially influencing cytokine signaling and immune response. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $172.00 $964.00 | 2 | |
Multi-kinase inhibitor, potentially affecting cell signaling related to growth and survival. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
CDK4/6 inhibitor, potentially impacting cell cycle regulation and proliferation. | ||||||
Neratinib | 698387-09-6 | sc-364549 sc-364549A sc-364549B sc-364549C sc-364549D | 5 mg 25 mg 100 mg 500 mg 1 g | $90.00 $210.00 $375.00 $740.00 $1225.00 | 4 | |
Pan-HER inhibitor, potentially affecting epidermal growth factor receptor signaling pathways. | ||||||
Lenvatinib | 417716-92-8 | sc-488530 sc-488530A sc-488530B | 5 mg 25 mg 100 mg | $178.00 $648.00 $1657.00 | 3 | |
Multi-kinase inhibitor, potentially impacting angiogenesis and cell proliferation. | ||||||